Investigational New Drugs

, Volume 30, Issue 2, pp 714–722

A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response

  • Robert M. Rifkin
  • Andrew Greenspan
  • John F. Schwerkoske
  • Romeo A. Mandanas
  • Joe J. Stephenson
  • George T. Kannarkat
  • Feng Zhan
  • Kristi A. Boehm
  • Lina Asmar
  • Roy Beveridge
PHASE II STUDIES

DOI: 10.1007/s10637-010-9556-6

Cite this article as:
Rifkin, R.M., Greenspan, A., Schwerkoske, J.F. et al. Invest New Drugs (2012) 30: 714. doi:10.1007/s10637-010-9556-6

Summary

Background A majority of multiple myeloma (MM) patients fail to achieve complete response (CR) to peripheral blood stem cell transplantation (PBSCT); effective options following autologous transplantation are needed. Bortezomib (B) is active against MM. This study was conducted to determine the feasibility, safety, tolerability, and efficacy of B following high-dose melphalan therapy and PBSCT. Methods Fifty patients enrolled (48 evaluable) and 49 were treated (safety population). Treatment: 4 cycles B 1.3 mg/m2 Days 1, 4, 8, and 11/21-days; 4 additional cycles were permitted for stable or responding patients. Results Median age was 55 years (range, 38–73), 68% male, 64% ECOG PS = 0, 44% Durie-Salmon Stage IIIA prior to induction, 42% had symptomatic IgG MM; 74% had prior single transplant (26% tandem). Responses post-transplant: 70% PRs, 18% MRs. A median of 4 cycles (range, 2–8) of B were administered. Responses: CR 8%, uCR 2%, PR 23%, uPR 19%, MR 10%, and no change 35%; median time-to-treatment failure (TTF) was 6.2 months (range, 1.0–19.4). Three deaths occurred (n = 1 sepsis, n = 2 disease progression). Grade 3–4 treatment-related toxicities included: thrombocytopenia, neuropathy (14%, each); asthenia, neutropenia (10%, each); and nausea (4%). Twelve patients (24%) discontinued treatment due to toxicity and 30 patients (60%) completed the study; 20 patients started new treatment (median 5.8 months [range, 1.5–20.3]). Conclusions The study closed early due to widespread availability of B, and the lack of B-naïve patients. Bortezomib monotherapy after melphalan and autologous PBSCT was feasible, safe and well-tolerated (toxicities were manageable), but failed to produce the hypothesized response rates.

Keywords

AutologousBortezomibCommunity-basedMulticenterPeripheral blood stem cell transplantProteasome inhibition

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Robert M. Rifkin
    • 1
    • 2
    • 8
  • Andrew Greenspan
    • 1
    • 3
  • John F. Schwerkoske
    • 1
    • 4
  • Romeo A. Mandanas
    • 1
    • 5
  • Joe J. Stephenson
    • 1
    • 6
  • George T. Kannarkat
    • 1
    • 7
  • Feng Zhan
    • 1
  • Kristi A. Boehm
    • 1
  • Lina Asmar
    • 1
  • Roy Beveridge
    • 1
    • 7
  1. 1.US Oncology Research, Inc.The WoodlandsUSA
  2. 2.Rocky Mountain Cancer CentersDenverUSA
  3. 3.Central Indiana Cancer CentersIndianapolisUSA
  4. 4.Minnesota Oncology HematologySt. PaulUSA
  5. 5.Cancer Care Associates–WestOklahoma CityUSA
  6. 6.Cancer Centers of the CarolinasGreenvilleUSA
  7. 7.Fairfax Northern Virginia Hematology OncologyFairfaxUSA
  8. 8.Rocky Mountain Cancer CentersUS Oncology Research, Inc.DenverUSA